Pembrolizumab Demonstrates Improved Overall Survival as Initial Treatment of Recurrent or Metastatic HNSCC – APhA submits compounding comments to FDA.

5Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Pembrolizumab Demonstrates Improved Overall Survival as Initial Treatment of Recurrent or Metastatic HNSCC – APhA submits compounding comments to FDA. – (866) 348-2889.

Merck’s pembrolizumab (Keytruda) injection, an anti-PD-1 therapy, in combination with chemotherapy has been found to reduce the risk of death by 40% in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors expressed PD-L1 with a combined positive score equal to or less than 20. In the Phase 3 KEYNOTE-048 trial, the combination demonstrated significantly longer overall survival when compared to the regimen of cetuximab with carboplatin or cisplatin plus 5-fluorouracil (Extreme), which is the current standard of care.1

The data was announced today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.